Supernus Reports Final Audited Fourth Quarter and Full Year 2021 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- Wall St indexes advance with boost from chips, Iran optimism
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- SanDisk and Micron surge as Apple confirms memory price pass-through
- Zelenskiy: best guarantee of Europe's future is fast-track EU membership for Ukraine
- Needham Starts NeoVolta (NEOV) at Buy
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Supernus Pharma (SUPN) Reports Q4 EPS of $0.04
April 13, 2022 4:13 PM EDTSupernus Pharma (NASDAQ: SUPN) reported Q4 EPS of $0.04, versus $0.57 reported last year. Revenue for the quarter came in at $159.1 million, versus $143.6 million reported last year.
GUIDANCE:
Supernus Pharma sees FY2022 revenue of $640-680 million.
For earnings history and earnings-related data on Supernus Pharma (SUPN) click here.
... More